Colorectal Cancer

>

Latest News

Exercise-Based Regimen Shows Efficacy Promise in CRC
Exercise-Based Regimen Shows Efficacy Promise in CRC

June 30th 2025

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

June 28th 2025

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

June 23rd 2025

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases
Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

June 20th 2025

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC
Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

June 17th 2025

More News